-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John F. Coelho, Appointed to Board of Directors in May 2022- TARRYTOWN, NY, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on… Read More..

ATLANTA, August 04, 2022--BUSINESS WIRE--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its second quarter 2022 financial results will be reported on Thursday, August 11, 2022 before the open of the financial markets. Management… Read More..

Bubblr Advances its Mission to Fix Fundamental Flaws in the Current Internet Economic Model with Key Patent Wins Current Awards Follows Patent Approval in U.S., South Africa and New Zealand NEW YORK, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Bubblr Inc., (OTC PINK: BBLR), ("Bubblr" or the "Company"), the… Read More..